Emerging research demonstrates the increasing stability of attenuation on clinically relevant VMIs with photon-counting CT and a redefined role of kV that may have implications for longitudinal quantitative CT.
|Articles|April 7, 2004
Oncology software assets change hands
Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell,
Advertisement
Varian Medical Systems has acquired the assets of Denver-based OpTx, a privately held supplier of software for medical oncology practices. Varian, which paid approximately $18 million cash to obtain the assets, plans to continue to develop, sell, install, and service OpTxTools software worldwide as a stand-alone product for medical oncology practices and as part of its VARiS software for coordination with radiation oncology. With this acquisition, Varian is able to offer an integrated single software system for managing and coordinating radiation therapy and chemotherapy routinely used in the treatment of cancer, according to the company. The acquisition is expected to add annualized revenues of $9 million to Varian coffers and be nearly neutral to earnings for the company in fiscal year 2004.
Advertisement
Related to this article
For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.
In the second of a two-part podcast episode, Lauren Nicola, MD, Christoph Wald, MD, PhD, MBA, and Peter Shen discuss challenges with evaluating value and ROI for AI software, the physician time required to do so, and possible solutions to facilitate improved clarity and consistency with AI reimbursement.
In the latest episode of her “Breast Imaging in Focus” series, Manisha Bahl, MD, MPH, FSBI, offer pertinent takeaways for breast radiologists from recently issued guidelines for addressing proliferative breast lesions with atypia and lobular carcinoma in situ (LCIS).
In a study involving over 2,800 people who had brain MRI scans, researchers found that people in the most disadvantaged neighborhoods had 37 percent higher white matter hyperintensity volume (WMHV) on average in comparison to people in the least disadvantaged areas.
In the second of a two-part interview, Kalpana Kanal, PhD, and Mahadevappa Mahesh, MS, PhD, FAPPM, FACR, discussed future directions for research on CT radiation dosing, including the potential of indication-specific diagnostic reference levels (DRLs).
Amid the explosion of imaging volume, an emerging silver lining is increasing recognition from referring clinicians of the time and value radiologists provide to facilitate patient care.
In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Prostate MRI Study Links Lower ACD Values on DWI to Higher Long-Term Risk of Distant Metastases
2
The Reading Room Podcast: Assessing the Current Landscape of AI and Reimbursement in Radiology, Part 2
3
Breast Imaging in Focus: Key Pearls from New Guidelines on Proliferative Breast Lesions with Atypia and LCIS
4
Molecular Imaging in Focus: Can the Newly FDA-Approved PET Agent Floretyrosine F18 Have an Impact for Glioma Imaging?
5